| Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD) |
2015-004524-65: Efficacy of a vaccine with nine subgroups against human papilloma virus in HIV infected sexually active men who have sex with men. Effekten af en vaccine indeholdende ni undergrupper mod humant papilloma virus hos HIV smittede seksuelt aktive mænd der har sex med mænd. |
|
|
| Ongoing | 4 | 80 | Europe | Gardasil 9, Suspension for injection | Department of Infectious Diseases, AIDS- Foundation, Odense University Hospital Research Foundation | The purpose of the study is to investigate the efficacy of a new nonavalent HPV vaccine in sexually active HIV-infected MSM. Formålet med forsøget er at undersøge effekten af en ny ni-valent HPV vaccine hos seksuelt aktive, HIV-smittede MSM., The purpose of the study is to investigate the effect of a new vaccine , which contains nine subgroups against human papilloma virus among sexually active HIV-infected men who have sex with men . Formålet med forsøget er at undersøge effekten af en ny vaccine, som indeholder ni undergrupper mod humant papilloma virus hos seksuelt aktive, HIV-smittede mænd der har sex med mænd., Diseases [C] - Virus Diseases [C02] | | | | |
2018-000215-24: A trial to evaluate the immunogenicity of vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017 Study Ensayo clínico sobre la inmunogenicidad de la vacuna frente al virus del papiloma humano en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA 10017 |
|
|
| Ongoing | 4 | 166 | Europe | Suspension for injection in pre-filled syringe, Gardasil 9 | Fundacion SEIMC-GESIDA, Merck Sharp & Dohme | AIDS SIDA, AIDS SIDA, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-002764-94: Human papilloma virus (HPV) VACcination after surgical treatment of precursor lesions for cervical cancer. Vaccinatie met humaan papillomavirus (HPV) na chirurgische behandeling van voorloopstadia voor baarmoederhalskanker. |
|
|
| Not yet recruiting | 4 | 750 | Europe | gardasil 9, PRD4575517, Solution for injection, Gardasil 9 | Erasmus MC, MSD vaccins, ZonMw | Human papilloma virus (HPV) causes cervical cancer. HPV vaccination is highly effective in primary prevention. There is less known about a possible secondary effect in women already infected with HPV. Our study proposes to investigate this efficacy in women with precursors of cervical cancer. HPV vaccination after surgical treatment to evaluate the efficacy to prevent recurrent disease. Humaan papillomavirus (HPV) veroorzaakt baarmoederhalskanker. HPV-vaccinatie is zeer effectief in primaire preventie. Er is minder bekend over een mogelijk secundair effect bij vrouwen die al met HPV zijn geïnfecteerd. Onze studie stelt voor om deze werkzaamheid te onderzoeken bij vrouwen met precursoren van baarmoederhalskanker.HPV-vaccinatie na chirurgische behandeling om de werkzaamheid te evalueren om recidiverende ziekte te voorkomen., Precursor lesions of cervical cancer are caused by HPV. Vaccination with HPV-vaccine after LEEP to prevent recurrent disease. Voorloopstadia van baarmoederhalskanker worden veroorzaakt door HPV. Vaccinatie met HPV-vaccin na een lisexcisie om recidiverende ziekte te voorkomen, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2020-001169-34: Women aged 23-25 that are invited and participating in the organised cervical screening program of Sweden will be offered 2 doses of Gardasil 9 at their first and second visit, with 3 years apart. This in line with WHO's directives to eliminate cervical cancer worldwide. |
|
|
| Not yet recruiting | 4 | 150000 | Europe | Gardasil 9, Suspension for injection, Gardasil 9 | Region Stockholm, Region Stockholm | HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer., Cervical cellular changes and tumour in the cervix., Diseases [C] - Cancer [C04] | | | | |
2021-005229-26: A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination. Estudio abierto, no aleatorizado para evaluar la reducción de la infectividad y la transmisión del virus del papiloma humano (VPH) en mujeres positivas al VPH después de la vacunación con 9vHPV. |
|
|
| Not yet recruiting | 4 | 69 | Europe | Suspension for injection, Gardasil 9 | Dr. Miguel Angel Pavón Ribas, Instituto de Salud Carlos III, MSD | Human Papillomavirus Virus del Papiloma Humano, Human Papillomavirus Virus del Papiloma Humano, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 4 | 225 | US | Gardasil9 | Johns Hopkins University, Merck Sharp & Dohme LLC | HPV, Immunization, Human Papilloma Virus | 07/22 | 02/23 | | |
| Active, not recruiting | 4 | 158 | Europe | Human Papillomavirus 9-valent Vaccine, Recombinant | University Hospital Virgen de las Nieves, Instituto de Salud Carlos III | HIV Infections, HPV Infection | 09/24 | 12/24 | | |
| Active, not recruiting | 4 | 1000 | Canada | HPV vaccine, Gardasil 9, Hepatitis A vaccine, Avaxim | McGill University | Human Papillomavirus Infection | 12/22 | 12/22 | | |
NCT04982614: HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini |
|
|
| Completed | 4 | 1403 | RoW | Gardasil ® 9, Human Papillomavirus 9-valent Vaccine, Recombinant, 9vHPV vaccine | Columbia University, Jhpiego, Merck Sharp & Dohme LLC | HPV Infection, Hiv, HPV Vaccine | 09/23 | 07/24 | | |
NCT03350698: Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination |
|
|
| Recruiting | 4 | 100 | US | Gardasil-9 | Eastern Virginia Medical School, Merck Sharp & Dohme LLC | Papillomavirus Vaccines | 12/23 | 12/23 | | |
| Active, not recruiting | 4 | 2275 | RoW | immediate Gardasil 9, delayed MenVeo vaccine, immediate MenVeo vaccine, delayed Gardasil 9, immediate Cervarix, delayed MenVeo vaccine | Massachusetts General Hospital, Bill and Melinda Gates Foundation, Kenya Medical Research Institute | Papillomavirus Infections | 02/24 | 02/24 | | |
NCT03943875: GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose |
|
|
| Active, not recruiting | 4 | 757 | US | 9-valent HPV vaccine, 2 dose efficacy, 9-valent HPV vaccine, 3 doses standard timing | The University of Texas Medical Branch, Galveston, Cancer Prevention Research Institute of Texas | Immunization, Efficacy, Human Papilloma Virus | 03/25 | 03/26 | | |
NCT04206813: An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen |
|
|
| Active, not recruiting | 4 | 352 | US | Gardasil 9 2 dose regimen, Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9 3 dose regimen, Gardasil 9 rescue dose | Boston Medical Center, Merck Sharp & Dohme LLC | HPV Infection | 08/25 | 08/25 | | |
NCI-2018-02606, NCT03023631: Gardasil 9 Vaccine in Preventing HPV Infection in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
|
|
| Active, not recruiting | 4 | 48 | US | Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm | 05/25 | 05/25 | | |
| Recruiting | 4 | 150 | US | Human papillomavirus 9-valent vaccine, recombinant, Gardasil-9 | Louisiana State University Health Sciences Center in New Orleans, Merck Sharp & Dohme LLC | Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection | 06/24 | 03/25 | | |
| Recruiting | 4 | 120 | Europe | 9-valent HPV vaccine | Talia Sainz Costa | Human Papilloma Virus Infection | 09/24 | 03/25 | | |
NCT06536855: Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda |
|
|
| Not yet recruiting | 4 | 100000 | NA | Gardasil 9, HPV/DNA testing (Gynotyping) | Rwanda Biomedical Centre, Merck Sharp & Dohme LLC, Karolinska Institutet, Center for Family Health Research/Projet San Francisco, ELEKTA Foundation | Cervical Cancer | 03/25 | 03/26 | | |
HOPE II, NCT06436274: Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. |
|
|
| Recruiting | 4 | 750 | RoW | GARDASIL®9, Menveo®/Menactra® | Massachusetts General Hospital, University of Witwatersrand, South Africa, Botswana Harvard Health Partnership, Ministry of Health, Rwanda, Fred Hutchinson Cancer Center, National Cancer Institute (NCI), Karolinska Institutet | Human Papilloma Virus, Hiv | 04/26 | 06/27 | | |
| Not yet recruiting | 4 | 100 | US | Gardasil-9, HPV Vaccine, 9-valent HPV vaccine (9vHPV), Lidocaine injection, Lidocaine 1% Injectable Solution, Lorazepam | Emory University, Merck Sharp & Dohme LLC | HPV | 03/28 | 03/28 | | |
NCT03180034: Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study |
|
|
| Active, not recruiting | 4 | 28000 | RoW | Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | National Cancer Institute (NCI), Bill and Melinda Gates Foundation | Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma | 08/25 | 08/25 | | |
NCT04910802: Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden |
|
|
| Recruiting | 4 | 150000 | Europe | Gardasil9 | Miriam Elfström, Karolinska University Hospital | HPV Infection, CIN 2/3, Cervical Cancer | 12/25 | 12/27 | | |
NCT05557370: Immunogenicity of HPV Vaccine in Transplant Recipients. |
|
|
| Recruiting | 4 | 30 | US | Human Papilloma Virus vaccine (GARDASIL 9) | Medical College of Wisconsin, Merck Sharp & Dohme LLC | Chronic Kidney Diseases, Kidney Transplant | 12/25 | 12/35 | | |
NCT06786429: Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. |
|
|
| Not yet recruiting | 4 | 1800 | NA | Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy | Eunice Dube, National University of Science and Technology, Zimbabwe | Hepatitis B, Human Papilloma Virus, Gall Stones (& [Calculus - Gall Bladder]), Mental Health Issue, Cancer Liver, Cancer of Cervix, Depression, Anxiety | 09/30 | 09/30 | | |
PRISMA, NCT05237947: Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The ESCUDDO Trial |
|
|
| Active, not recruiting | 4 | 5000 | RoW | Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Adacel, Daptacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine Adsorbed, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine, DTaP, Infanrix, Tripedia, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine, Cervarix, GSK-580299, HPV 16/18 L1 VLP/AS04 VAC, HPV-16/18 VLP/AS04 Vaccine, Human Papillomavirus 16/18 L1 Virus-Like Particle/AS04 Vaccine, Human Papillomavirus Bivalent Types 16 and 18 Vaccine, Recombinant, Human Papillomavirus Vaccine L1 16,18, Human Papillomavirus Vaccine, L1 Type 16, 18, Recombinant HPV Bivalent Vaccine, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | National Cancer Institute (NCI) | Cervical Carcinoma, Human Papillomavirus Infection | 05/26 | 05/26 | | |
OPTIMO, NCT04265950: Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, Trial |
|
|
| Active, not recruiting | 4 | 97 | RoW | Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | Fred Hutchinson Cancer Center, Via Libre, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), National Cancer Institute (NCI), GHESKIO Center | HIV Infection | 09/26 | 10/26 | | |
NCT05672927: Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old) |
|
|
| Recruiting | 4 | 618 | US | 9-valent HPV vaccine, 2 doses alternate timing, 9-valent HPV vaccine, 3 doses standard timing | The University of Texas Medical Branch, Galveston, Cancer Prevention Research Institute of Texas | Immunization, HPV Infection, Human Papillomavirus | 08/26 | 08/27 | | |
| Not yet recruiting | 4 | 500 | Europe | Gardasil 9 Suspension for Injection, Placebo | Erasmus Medical Center, Dutch Cancer Society | Vulvar HSIL, HPV | 12/28 | 12/30 | | |
2021-000333-13: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts Efficacité du vaccin HPV nonavalent dans le traitement des verrues palmo-plantaires difficiles à traiter |
|
|
| Not yet recruiting | 3 | | Europe | Gardasil 9®, Suspension for injection, Gardasil 9 suspension for injection. | APHP DRCI | Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age La vaccination par un vaccin nonavalent contre le HPV peut conduire à une résolution complète des verrues palmo-plantaires difficiles à traiter chez les patients âgés de plus de 15 ans et 3 mois., Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age La vaccination par un vaccin nonavalent contre le HPV peut conduire à une résolution complète des verrues palmo-plantaires difficiles à traiter chez les patients âgés de plus de 15 ans et 3 mois, Diseases [C] - Virus Diseases [C02] | | | | |
2015-005093-38: A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old. |
|
|
| Ongoing | 3 | 1200 | Europe | Human Papillomavirus 9-valent Vaccine, Recombinant, V503, Suspension for injection, GARDASIL®9 | Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc, Sanofi Pasteur MSD S.N.C, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Sanofi Pasteur MSD S.N.C. | Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58, Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus, Diseases [C] - Virus Diseases [C02] | | | | |
2018-004662-33: HPV vaccine after treatment for cervical pre-invasive disease |
|
|
| Not yet recruiting | 3 | 1000 | Europe | Gardasil 9™, V503, Suspension for injection in pre-filled syringe, Gardasil 9™ | Imperial College London, National Institute of Health Research (NIHR), Merck Sharp & Dohme Ltd | Cervical intra-epithelial neoplasia, cervical high-grade pre-invasive lesions, Diseases [C] - Cancer [C04] | | | | |
V503-IC, NCT03482739: Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients |
|
|
| Active, not recruiting | 3 | 270 | Europe | nine-valent HPV vaccine, Gardasil9 | Universitaire Ziekenhuizen Leuven | Human Papilloma Virus, Human Immunodeficiency Virus, Solid Organ Transplant | 08/19 | 08/19 | | |
NCT02834637: A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls |
|
|
| Active, not recruiting | 3 | 930 | RoW | bivalent HPV vaccine, Cervarix, nonavalent HPV vaccine, Gardasil9 | London School of Hygiene and Tropical Medicine, University of York, Institut Català d'Oncologia, National Cancer Institute (NCI), Karolinska Institutet, Technische Universität Berlin, Tanzanian National Institute for Medical Research, University of Glasgow | Human Papilloma Virus | 01/20 | 03/27 | | |
2017-004322-15: A study of the safety, tolerability and immune response of a nine-valent human papillomavirus (HPV) vaccine (Gardasil®9) in HIV-infected patients (18 to 45 years of age) and solid organ transplant recipients (18 to 55 years of age). Een klinisch onderzoek om de veiligheid, verdraagbaarheid en immuun antwoord van GARDASIL®9 (een 9-waardig humaan papillomavirus [HPV] vaccin) te bestuderen bij HIV patiënten (18 tot 45 jaar) en transplantpatiënten (18 tot 55 jaar). |
|
|
| Not yet recruiting | 3 | 310 | Europe | Gardasil9, Solution for injection in pre-filled syringe, Gardasil9 | UZ Leuven, MSD Belgium BVBA | Immune response to HPV vaccination in HIV-patients and Solid Organ Transplant patients Immuunantwoord na HPV vaccinatie bij HIV patiënten en Vaste Orgaan Transplantpatiënten, Infections with human papillomavirus Infecties met humaan papillomavirus, Body processes [G] - Immune system processes [G12] | | | | |
2018-003507-19: Impact on Disease Relapse of HPV Vaccination in Women Treated With electrosurgical excision with diathermic loop (LEEP) for Cervical Intraepithelial Neoplasia. Impatto sulla recidiva di malattia della vaccinazione anti-HPV nelle donne trattate con escissione elettrochirurgica con ansa diatermica (LEEP) per neoplasia cervicale intraepiteliale. |
|
|
| Not yet recruiting | 3 | 1220 | Europe | GARDASIL9 0,5 ml - sospensione iniettabile - uso intramuscolare – siringa pre-riempita (vetro) - 1 s, [GARDASIL9 0, 5 ml - sospensione iniettabile - uso, Suspension for injection, GARDASIL9 0,5 ml - sospensione iniettabile - uso intramuscolare – siringa pre-riempita (vetro) - 1 siringa preriempita + 2 aghi | AZIENDA USL TOSCANA NORD OVEST, MSD ITALIA | Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1) Prevenzione della recidiva dopo un primo episodio di neoplasia cervicale intraepiteliale di alto grado (CIN2+) fino a cancro cervicale inizialmente invasivo (FIGO IA1), Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia up to initially invasive cervical cancer Prevenzione della recidiva di malattia dopo un primo episodio di neoplasia cervicale intraepiteliale di alto grado fino a cancro della cervice inizialmente invasivo, Diseases [C] - Cancer [C04] | | | | |
2020-003736-24: Safety and Immunogenicity of Extended 2-dose Regimens of 9vHPV Vaccine |
|
|
| Not yet recruiting | 3 | 700 | Europe | V503, Suspension for injection, GARDASIL®9 | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Prevention of persistent anogenital HPV infection and disease caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58, Body processes [G] - Immune system processes [G12] | | | | |
NCT04782895: Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age |
|
|
| Completed | 3 | 488 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 05/22 | 07/22 | | |
NCT05662020: A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China |
|
|
| Active, not recruiting | 3 | 2750 | RoW | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 | Beijing Health Guard Biotechnology, Inc, Yunnan Center for Disease Control and Prevention, Mile City Center for Disease Control and Prevention, Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Shanghai Stem Pharmaceutical Development Co., Ltd. | Human Papillomavirus Infection | 11/22 | 03/28 | | |
HOPE9, NCT03848039: Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. |
|
|
| Not yet recruiting | 3 | 1220 | NA | Gardasil-9, 9-valent HPV vaccine, Vaccine against HPV-6, 11, 16, 18, 31, 33, 45, 52, 58, Placebo, Sterile Water for Injection Ph. Eur. | Alessandro Ghelardi | Cervical Intraepithelial Neoplasia | 12/22 | 05/28 | | |
NCT05580341: Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 |
|
|
| Active, not recruiting | 3 | 1200 | RoW | Zerun HPV-9, GARDASIL ®9 | Shanghai Zerun Biotechnology Co.,Ltd, Walvax Biotechnology Co., Ltd. | Cervical Cancer, Genital Wart, CIN, VIN, Papillomavirus Infections | 06/23 | 12/23 | | |
| Active, not recruiting | 3 | 1000 | Europe | Gardasill 9™ vaccine | Imperial College London, National Institute of Health Research (NIHR), Merck Sharp & Dohme Ltd | Neoplasia | 08/25 | 08/25 | | |
| Active, not recruiting | 3 | 1260 | RoW | Nonavalent HPV study vaccine, Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 | Beijing Health Guard Biotechnology, Inc, University of Muhammadiyah Malang Hospital, Dr. M Djamil Hospital, Padang | Human Papillomavirus Infection | 11/24 | 01/26 | | |
V503-076, NCT05119855 / 2021-003591-13: Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine |
|
|
| Completed | 3 | 165 | US | 9vHPV Vaccine, V503, GARDASIL®9, SILGARD®9, mRNA-1273 Vaccine, SARS-CoV-2 Vaccine, Moderna COVID-19 Vaccine | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papillomavirus Infections, Coronavirus Disease (COVID-19) | 12/23 | 12/23 | | |
2020-001170-29: Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine inJapanese Boys and Girls |
|
|
| Not yet recruiting | 3 | 300 | Japan | V503, Suspension for injection, GARDASIL®9 | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papillomavirus Infections, Papillomavirus Infections, Body processes [G] - Immune system processes [G12] | | | | |
| Completed | 3 | 312 | Japan | 9vHPV vaccine, V503, SILGARD®9, GARDASIL™9 | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papillomavirus Infections | 04/24 | 04/24 | | |
2021-003591-13: Safety and Immunogenicity of 9vHPV Vaccine Coadministered With mRNA-1273 SARS-CoV-2 Vaccine |
|
|
| Not yet recruiting | 3 | 160 | US | Suspension for injection, Dispersion for injection, GARDASIL®9 (9vHPV vaccine), mRNA-1273 SARS-CoV-2 vaccine | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papilloma viral infection, Papilloma viral infection, Body processes [G] - Immune system processes [G12] | | | | |
NCT03832049: HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial |
|
|
| Active, not recruiting | 3 | 1720 | RoW | 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses, 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose | London School of Hygiene and Tropical Medicine, Public Health England, University of Cambridge, Merck Sharp & Dohme LLC | Human Papillomavirus Vaccine | 06/24 | 06/24 | | |
| Recruiting | 3 | 450 | Canada | Nonavalent HPV vaccine, Gardasil9 | University of British Columbia | HPV, Human Papilloma Virus, Human Immunodeficiency Virus | 08/24 | 08/26 | | |
| Active, not recruiting | 3 | 8100 | RoW | 9vHPV Vaccine, V503, Placebo | Merck Sharp & Dohme LLC | Papillomavirus Infections | 05/29 | 05/29 | | |
2024-000582-24: Immunobridging study of 9vHPV vaccine in Chinese females 9 to 45 years of age |
|
|
| Not yet recruiting | 3 | 1990 | RoW | Suspension for injection, GARDASIL®9 (9vHPV vaccine) | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papillomavirus Infections, Papillomavirus Infections, Body processes [G] - Immune system processes [G12] | | | | |
| Active, not recruiting | 3 | 1059 | Japan | V503, 9vHPV vaccine, SILGARD®9, GARDASIL™9, Placebo | Merck Sharp & Dohme LLC | Warts, Genital, Neoplasms, Anal | 12/23 | 08/25 | | |
| Active, not recruiting | 3 | 1990 | RoW | V503 | Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC | Papillomavirus Infections | 02/25 | 02/25 | | |
COVENANT, NCT03284866: HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV |
|
|
| Active, not recruiting | 3 | 536 | RoW | Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Recombinant HPV 9-valent Vaccine, Saline, Sodium Chloride 0.9% | AIDS Malignancy Consortium, National Cancer Institute (NCI), University of Arkansas, AIDS and Cancer Specimen Resource, Merck Sharp & Dohme LLC, The Emmes Company, LLC, University of California, Los Angeles | AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection | 12/24 | 03/27 | | |
NCT04255849: Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV |
|
|
| Active, not recruiting | 3 | 700 | US, RoW | 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo | Weill Medical College of Cornell University, H. Lee Moffitt Cancer Center and Research Institute, University of Sao Paulo, University of Puerto Rico, Mexican National Institute of Public Health, National Cancer Institute (NCI), Merck Sharp & Dohme LLC | HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection | 04/26 | 04/26 | | |
| Active, not recruiting | 3 | 6033 | Europe, Japan, US, RoW | 9vHPV Vaccine, GARDASIL®9, V503, Placebo (Saline for Injection) | Merck Sharp & Dohme LLC | Papillomavirus Infections | 09/26 | 09/26 | | |
| Active, not recruiting | 3 | 6000 | RoW | V503, Gardasil | Merck Sharp & Dohme LLC | Papillomavirus Infections | 03/28 | 03/28 | | |
| Active, not recruiting | 3 | 1590 | RoW | 9vHPV vaccine, V503, GARDASIL™9 | Merck Sharp & Dohme LLC | Genital Warts | 02/29 | 02/29 | | |
V503-069, NCT04708041: Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine |
|
|
| Active, not recruiting | 3 | 700 | Europe, US, RoW | 9vHPV vaccine | Merck Sharp & Dohme LLC | Papillomavirus Infections | 06/29 | 06/29 | | |
| Active, not recruiting | 3 | 1500 | RoW | 9vHPV vaccine, V503, GARDASIL9™ | Merck Sharp & Dohme LLC | Papillomavirus Infections | 08/29 | 08/29 | | |
NCT05625633: Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts |
|
|
| Recruiting | 2/3 | 120 | US | Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9, 9-valent Gardasil, Normal Saline | Western Institute for Veterans Research, University of Utah, Merck Sharp & Dohme LLC | Warts | 12/25 | 12/26 | | |
NCT02568566: Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants |
|
|
| Active, not recruiting | 2 | 201 | US | Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | National Cancer Institute (NCI) | Human Papillomavirus-Related Carcinoma | 02/20 | 01/26 | | |
2021-003895-15: Human papillomavirus (HPV) vaccination for treatment of premalignant skin lesions Humant papillomvirus (HPV) vaccination til behandling af hudkræftforstadier |
|
|
| Not yet recruiting | 2 | 70 | Europe | Gardasil® 9, Suspension for injection in pre-filled syringe, Gardasil® 9 | Bispebjerg Hospital, Department of Dermatology and Venereology, Interne Forskningsmidler Bispebjerg og Frederiksberg Hospital, Fonden Af Fam. Kjærsgaard, Sunds, Michael Hermann Nielsens Mindelegat afd. B, Region Hovedstadens Forskningsfond til Sundhedsforskning | Actinic Keratosis (AK), Precursors to skin cancer, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02864147: Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) |
|
|
| Completed | 2 | 134 | US | 9-valent HPV vaccine, Imiquimod | Yale University | Cervical Intraepithelial Neoplasia, Cervical Dysplasia | 05/22 | 11/22 | | |
NCT05060484: A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years |
|
|
| Recruiting | 2 | 1800 | RoW | SCT1000, Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells), Gardasil®9, Gardasil®, placebo | Sinocelltech Ltd. | Interventional, Prevention, Randomized | 05/22 | 07/22 | | |
NCT03036930: Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients |
|
|
| Active, not recruiting | 2 | 52 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, HPV Self-Collection, At-home HPV Self Collection, HPV Self Collection, Human Papillomavirus Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine | National Cancer Institute (NCI) | Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma | 03/24 | 03/25 | | |
NCT03519464: Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia |
|
|
| Active, not recruiting | 2 | 54 | US | Gardasil 9 | National Institute of Allergy and Infectious Diseases (NIAID) | Idiopathic CD4 T Cell Lymphocytopenia | 12/26 | 12/26 | | |
RIFT-HPV, NCT05334706: A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV |
|
|
| Recruiting | 2 | 69 | Europe | Nonavalent HPV vaccine (9vHPV/Gardasil-9™). | Miquel Angel Pavon Ribas, Hospital del Mar, Catalan Institute of Health | Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18 | 05/24 | 05/24 | | |
HPV2-2303, NCT06658405: Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions |
|
|
| Not yet recruiting | 2 | 85 | Europe | Human Papillomavirus 9-valent Vaccine, Recombinant, Gardasil 9 | Centre Oscar Lambret, Canceropôle Nord Ouest | Cervical Lesion | 10/28 | 10/31 | | |
HPV9vxFSW, NCT06681636: Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure |
|
|
| Not yet recruiting | 2 | 300 | RoW | Human papillomavirus 9-valent vaccine, Recombinant, Gardasil 9 | National Institute of Hygiene and Epidemiology, Vietnam, Murdoch Childrens Research Institute, CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES, Hai phong Center for Disease Control | HPV Infection, Cervical Cancer, Anogenital Cancer, Anogenital Warts | 10/26 | 12/27 | | |
NCT06793410: Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation |
|
|
| Not yet recruiting | 2 | 100 | Europe | Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9® | Vastra Gotaland Region | Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Diffuse Large B Cell Lymphoma (DLBCL) | 10/29 | 10/29 | | |
PROTECT, NCT06624839: Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in Sexual and Gender minoriTies |
|
|
| Not yet recruiting | 2 | 180 | NA | Human papillomavirus (HPV) vaccine, 9-valent, Gardasil9 | University of Maryland, Baltimore | Transgender Persons, Human Papilloma Virus, Anal Dysplasia | 01/27 | 01/28 | | |
NCT03947775: HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL |
|
|
| Not yet recruiting | 2 | 228 | Canada | 9-valent HPV vaccination, Gardasil-9 | University Health Network, Toronto, Merck Sharp & Dohme LLC | Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus | 03/26 | 05/26 | | |
2022-000090-15: A study on the immune response and safety of an adjuvanted human papillomavirus vaccine when given to healthy women 16 to 26 years of age |
|
|
| Not yet recruiting | 1/2 | 1080 | Europe, RoW | Gardasil 9 suspension for injection, GSKVx000000031164, GSKVx000000031166, GSKVx000000031168, Suspension for injection, Suspension for injection in pre-filled syringe, Gardasil 9 | GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA | Active immunisation for the prevention of human papillomavirus infection, Prevention of human papillomavirus infection, Diseases [C] - Virus Diseases [C02] | | | | |
NCT05496231 / 2022-000090-15: A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age |
|
|
| Completed | 1/2 | 1080 | Europe, US, RoW | HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9 | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Cervical Intraepithelial Neoplasia | 02/24 | 02/24 | | |
NCT04921111: A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years |
|
|
| Recruiting | 1 | 240 | RoW | SCT1000, Recombinant 14 valent Human Papillomavirus Vaccine, Gardasil®9, Recombinant 9 valent human papillomavirus vaccine, placebo, aluminium phosphate, Gardasil®, Recombinant 4 valent human papillomavirus vaccine | Sinocelltech Ltd. | HPV Infection Vaccine Safety SCT1000 | 07/22 | 10/22 | | |
NCT02403505: Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer |
|
|
| Active, not recruiting | 1 | 20 | US | CEA protein antigen plus BCG Vaccine Mix for percutaneous use, CEA protein antigen plus BCG Organism Mix | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare | Rectal Cancer | 02/25 | 02/25 | | |
NCT06623409: Safety and Immunogenicity of V540B in Healthy Adults (V540B-002). |
|
|
| Recruiting | 1 | 72 | US | GARDASIL®9 (G9), V503, V540B | Merck Sharp & Dohme LLC | Healthy | 04/26 | 04/26 | | |
NCT06688058: A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004) |
|
|
| Recruiting | 1 | 72 | US | V540D, GARDASIL®9, G9, V503 | Merck Sharp & Dohme LLC | Healthy | 02/27 | 02/27 | | |
NCT05985681: Testing RG1-VLP Vaccine to Prevent HPV-related Cancers |
|
|
| Not yet recruiting | 1 | 33 | Europe, US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, HPV16 RG1 VLP Vaccine, 16L1-16L2aa17-36-based Vaccine, HPV16 RG1-VLP, HPV16-RG1VLPs, RG1-VLP Vaccine, RG1-VLPs, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9% | National Cancer Institute (NCI) | Human Papillomavirus-Related Carcinoma | 06/26 | 06/27 | | |
NCT05329961: Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old |
|
|
| Active, not recruiting | 1 | 150 | US | Gardasil9, GARDASIL® | Boston Medical Center, Merck Sharp & Dohme LLC | Human Papilloma Virus | 07/28 | 12/28 | | |
NCT06752083: Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection |
|
|
| Completed | N/A | 219 | Europe | AHCC® (Active Hexose Correlated Compound), Lentinula edodes supplement, Papion®, Gardasil 9® | Liaquat University of Medical & Health Sciences, Università degli Studi dell'Insubria | HPV Infection | 06/24 | 12/24 | | |
NCT06197802: Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women |
|
|
| Active, not recruiting | N/A | 392 | RoW | Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9 | Xiamen University, Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Cervical Cancer, Condylomata Acuminata | 03/25 | 03/25 | | |
V503-021, NCT02653118: Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women |
|
|
| Active, not recruiting | N/A | 4453 | NA | V503, GARDASIL | Merck Sharp & Dohme LLC | Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts, Human Papillomavirus Infection | 01/40 | 01/40 | | |
NCT06229353: Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department |
|
|
| Recruiting | N/A | 610 | US | Gardasil 9, Human Papillomavirus Vaccine, HPV vaccine | University of Alabama at Birmingham, Merck Investigator Studies Program | Human Papilloma Virus | 02/25 | 07/25 | | |
| low-dose freeze-dried recombinant tuberculosis vaccine (AEC/BCO2) / Chongqing Zhifei |
NCT05284812: A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) |
|
|
| Suspended | 2 | 200 | RoW | Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02), High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02), Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Tuberculosis | 06/24 | 12/24 | | |
| Zifivax (ZF2001) / Chinese Academy of Medical Sciences, Chongqing Zhifei |
| Recruiting | 4 | 100000 | RoW | Recombinant new coronavirus vaccine (CHO cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Hunan Provincial Center for Disease Control and Prevention, Guizhou Center for Disease Control and Prevention, Hainan Center for Disease Control & Prevention | COVID-19 | 06/22 | 06/23 | | |
ChiCTR2200057278: Immunogenicity Study on Booster Immunization of Different COVID-19 Vaccines |
|
|
| Recruiting | 4 | 1000 | | Intramuscular Ad5-nCoV ;Aerosol Ad5-nCoV ;Intramuscular ZF2001 ;Intramuscular inactivated vaccine ;Aerosol Ad5-nCoV | Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China; Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China, Ministry of Science and Technology of China | COVID-19 | | | | |
NCT05091411: Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) |
|
|
| Recruiting | 3 | 1680 | RoW | Recombinant new coronavirus vaccine (CHO cell) group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus Disease 2019 | 11/21 | 12/22 | | |
NCT04646590: A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 |
|
|
| Active, not recruiting | 3 | 28904 | RoW | Recombinant new coronavirus vaccine (CHO cell) group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Prevention of COVID-19, Safety and Efficacy | 11/21 | 12/22 | | |
NCT05107375: Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine |
|
|
| Completed | 3 | 299 | RoW | Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus Disease 2019 | 03/22 | 03/22 | | |
NCT05128643: Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) |
|
|
| Active, not recruiting | 3 | 300 | RoW | Recombinant novel coronavirus vaccine (CHO cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus Disease 2019 | 04/22 | 10/22 | | |
NCT05664932: Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above |
|
|
| Active, not recruiting | 3 | 1200 | RoW | Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001 | Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd. | COVID-19 | 01/23 | 12/23 | | |
NCT04466085: Clinical Study of Recombinant Novel Coronavirus Vaccine |
|
|
| Active, not recruiting | 2 | 900 | RoW | Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus | 10/20 | 12/21 | | |
NCT05109598: Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell) |
|
|
| Completed | 2 | 400 | RoW | Recombinant new coronavirus vaccine (CHO cell) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | COVID-19 | 02/22 | 04/23 | | |
NCT05205083: Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV |
|
|
| Recruiting | 1/2 | 480 | RoW | Recombinant novel coronavirus vaccine (CHO cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Zhejiang Provincial Center for Disease Control and Prevention | COVID-19 | 03/22 | 07/22 | | |
NCT05205096: Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac |
|
|
| Completed | 1/2 | 480 | RoW | Recombinant novel coronavirus vaccine (CHO cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Zhejiang Provincial Center for Disease Control and Prevention | COVID-19 | 06/22 | 07/22 | | |
NCT05198063: ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization |
|
|
| Completed | 1/2 | 300 | RoW | Recombinant novel coronavirus vaccine (CHO cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Prevention of COVID-19 | 08/22 | 12/22 | | |
NCT04445194: Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine |
|
|
| Active, not recruiting | 1 | 50 | RoW | Recombinant new coronavirus vaccine (CHO cell) low-dose group, Recombinant new coronavirus vaccine (CHO cells) high-dose group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao Yang Hospital | Coronavirus | 10/20 | 09/21 | | |
NCT04550351: Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old) |
|
|
| Active, not recruiting | 1 | 50 | RoW | Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus | 12/20 | 12/21 | | |
NCT04961359: Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) |
|
|
| Completed | 1 | 75 | RoW | Recombinant new coronavirus vaccine (CHO cell) group, Recombinant new coronavirus vaccine (CHO cells) placebo group | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Coronavirus | 12/21 | 04/23 | | |
NCT05895110: To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2 |
|
|
| Completed | N/A | 240 | RoW | Recombinant Novel Coronavirus vaccine (CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | COVID-19 | 11/22 | 11/22 | | |
